Last reviewed · How we verify
IVF-M HP Inj.
IVF-M HP is a recombinant human follicle-stimulating hormone (FSH) that stimulates ovarian follicle development and estrogen production in women undergoing assisted reproductive therapy.
IVF-M HP is a recombinant human follicle-stimulating hormone (FSH) that stimulates ovarian follicle development and estrogen production in women undergoing assisted reproductive therapy. Used for Anovulation or oligoovulation in women with polycystic ovary syndrome (PCOS) undergoing assisted reproduction, Controlled ovarian hyperstimulation for in vitro fertilization (IVF), Ovulation induction in infertile women.
At a glance
| Generic name | IVF-M HP Inj. |
|---|---|
| Sponsor | LG Life Sciences |
| Drug class | Gonadotropin (recombinant FSH) |
| Target | FSH receptor (FSHR) |
| Modality | Small molecule |
| Therapeutic area | Reproductive Medicine / Fertility |
| Phase | FDA-approved |
Mechanism of action
This injectable gonadotropin binds to FSH receptors on ovarian granulosa cells, promoting follicular growth and maturation during controlled ovarian hyperstimulation. By elevating circulating FSH levels, it enables the development of multiple mature oocytes suitable for retrieval during in vitro fertilization procedures. The 'HP' designation typically indicates a highly purified formulation with reduced impurities compared to earlier urinary-derived preparations.
Approved indications
- Anovulation or oligoovulation in women with polycystic ovary syndrome (PCOS) undergoing assisted reproduction
- Controlled ovarian hyperstimulation for in vitro fertilization (IVF)
- Ovulation induction in infertile women
Common side effects
- Ovarian hyperstimulation syndrome (OHSS)
- Injection site reactions (pain, bruising, erythema)
- Headache
- Abdominal pain or bloating
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IVF-M HP Inj. CI brief — competitive landscape report
- IVF-M HP Inj. updates RSS · CI watch RSS
- LG Life Sciences portfolio CI